Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.


From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Reaxense aids in their synthesis and provision.


In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.


We employ our advanced, specialised process to create targeted libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.


Several key aspects differentiate our library:


  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.

  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.

  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.

  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.


PARTNER
Receptor.AI
 
UPACC
Q6UWY2

UPID:
PRS57_HUMAN

ALTERNATIVE NAMES:
Neutrophil serine protease 4; Serine protease 1-like protein 1

ALTERNATIVE UPACC:
Q6UWY2; B2RNW8

BACKGROUND:
Serine protease 57, identified by its alternative names Neutrophil serine protease 4 and Serine protease 1-like protein 1, plays a critical role in cleaving peptide bonds preferentially after Arg residues. This enzyme's capability to cleave unique residues such as citrulline and methylarginine underlines its significance in post-translational modifications.

THERAPEUTIC SIGNIFICANCE:
The exploration of Serine protease 57's enzymatic mechanisms offers a promising avenue for the development of novel therapeutic interventions. By elucidating its function, researchers can identify new pathways for targeting diseases, underscoring the enzyme's potential in advancing medical treatments.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.